Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05141149 · ClinicalTrials.gov registry record · Phase 1

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

A Phase 1 study of Pancreatic Cancer, sponsored by Prestige Biopharma Limited.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
4
Study locations

NCT05141149 is a Phase 1 study of Pancreatic Cancer that is actively recruiting participants, run by Prestige Biopharma Limited. The registered enrollment target is 80 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05141149, a Phase 1 study of Pancreatic Cancer, is actively recruiting participants, sponsored by Prestige Biopharma Limited.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
4
Study locations

Study Summary

The first in human clinical study is planned as an open-label, dose-escalation, and dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Part 1 as a PBP1510 single agent dose-escalation, and PBP1510 dose-escalation in combination with gemcitabine, and Part 2 as PBP1510 dose-expansion at the RP2D in combination with gemcitabine.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG PBP1510 (400mg/16mL)
  • DRUG Gemcitabine (1000 mg/m^2)

Study Locations (4)

Other

  • Monash Health - Melbourne
  • National Cancer Centre Singapore - Singapore

New York

  • Northwell Health / R.J. Zuckerberg Cancer Center - New Hyde Park

Madrid

  • Hospital Universitario La Paz - Madrid

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-06-05
Est. Completion 2026-12
Phase Phase 1

Sponsor

Prestige Biopharma Limited

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05141149

The ClinicalTrials.gov registry entry for NCT05141149 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Prestige Biopharma Limited, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which PBP1510 (400mg/16mL) is the first listed.

NCT05141149 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, Madrid.

Frequently Asked Questions

What is clinical trial NCT05141149 about?

NCT05141149 is a clinical study titled "First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer". The first in human clinical study is planned as an open-label, dose-escalation, and dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Part 1 as a PBP1510 single agent dose-...

What is the current status of trial NCT05141149?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-06-05. Estimated completion is 2026-12.

What conditions does trial NCT05141149 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT05141149?

The interventions under investigation include: PBP1510 (400mg/16mL) (DRUG), Gemcitabine (1000 mg/m^2) (DRUG).

Who is sponsoring clinical trial NCT05141149?

This trial is sponsored by Prestige Biopharma Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05141149 being conducted?

This trial has 4 study locations across New York, Madrid. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.